Compare Vertex Pharmaceuticals Incorporated (VRTX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $511.7 (market cap $127.55B), while State Street Real Estate Select Sector SPDR ETF trades at $41.66 (market cap $7.61B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.8× State Street Real Estate Select Sector SPDR ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| VRTX | XLRE | |
|---|---|---|
Market Cap | $127.55B | $7.61B |
Volume | 1,487,944 | 7,876,569 |
Sector | Health | Sector/Thematic |
52-Week High | $557.96 | $46.01 |
52-Week Low | $407.37 | $40.01 |
Typical Hold Time | 120 Days | 75 Days |
Enterprise Value | $121.68B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
XLRE (Real Estate Select Sector SPDR ETF) trades at $41.515, up 2.33% with a bearish technical bias from moving averages. The ETF focuses on 30 U.S. large-cap real estate holdings with a low 0.08% expense ratio. Recent news highlights competition from global real estate ETFs and sector pressure from rising bond yields, though some analysts see value in REITs for income and diversification.
Outlook: XLRE offers low-cost U.S. real estate exposure but faces headwinds from interest rate volatility and underperformance concerns versus digital infrastructure ETFs. Risks include Fed policy shifts and sector concentration, while opportunities lie in inflation hedging and dividend income. Investor sentiment is mixed amid macro uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
